[Loss of extremities caused by heparin-induced thrombocytopenia].
We report the cases of two patients who last lims as a result of heparin-induced thrombocytopenia (HIT). On the basis of these cases, the incidence, pathophysiology and the diagnosis of HIT are reviewed. For the diagnosis of HIT, the platelet aggregation test and ELISA are used. For HIT prophylaxis and treatment of thromboembolic complications is recommended Orgaran. Exact dosage schedules are provided.
Wenzl
M E
ME
Abteilung für Unfall- und Wiederherstellungschirurgie, Berufsgenossenschaftliches Unfallkrankenhaus Hamburg.
Leffringhausen
W
W
Scherlitzky
L
L
D000368:Aged; D000671:Amputation, Surgical; D001132:Arm / Q000098:blood supply*; D002809:Chondroitin Sulfates / Q000008:administration & dosage; D003871:Dermatan Sulfate / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D012307:Risk Factors; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000601:surgery; D013927:Thrombosis / Q000139:chemically induced* / Q000175:diagnosis / Q000601:surgery
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005343:Fibrinolytic Agents; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid
Extremitätenverluste bei heparininduzierter Thrombozytopenie.